Cha Vaccine Institute Inc. (261780)

Overview

Cha Vaccine Research Institute Co., Ltd. stands as a pivotal entity in the biotechnology sector, dedicated to the exploration and creation of innovative vaccine solutions aimed at combating infectious and chronic ailments. Established in 2000, this research-intensive firm is strategically placed in Seongnam, South Korea, marking its presence as a leader in the vaccine development arena. Through its commitment to scientific excellence and its robust product development efforts, the company aims to address some of the most pressing healthcare challenges of our time.

Products and Services

• HBV Vaccine (Phase IIb)

  Designed as a preventive measure against hepatitis B, this vaccine has progressed to Phase IIb planning, showcasing Cha Vaccine Research Institute's commitment to combating this viral infection. Through meticulous research and development, the company aims to offer an effective solution to curb the spread of hepatitis B.

• Adjuvanted HBV Vaccine (Phase I/IIa)

  In the treatment landscape of chronic hepatitis B, the adjuvanted HBV vaccine presents a promising approach. Currently in Phase I/IIa, this innovative solution is tailored to enhance the immune response against the hepatitis B virus, offering hope for those battling chronic forms of the infection.

• VZV Vaccine (Pre-clinical Planning)

  The prevention of Herpes Zoster, commonly known as shingles, is the focus of the VZV Vaccine currently in the pre-clinical planning stage. By targeting the Varicella Zoster Virus, Cha Vaccine Research Institute seeks to develop a vaccine that could significantly reduce the incidence of this painful condition.

• Influenza Vaccine

  With seasonal flu posing a recurrent threat to public health, the company's influenza vaccine effort signifies an ongoing commitment to safeguard individuals from this contagious respiratory illness. Through advancing research in this area, the institute aims to contribute to global influenza prevention strategies.

• Recombinant MBL

  As part of its broader focus on infectious diseases, Cha Vaccine Research Institute is also developing recombinant Mannose-Binding Lectin (MBL), exploring its potential in enhancing immune defense mechanisms against a variety of pathogens.

• TB Vaccine

  Targeting tuberculosis, one of the world's deadliest infectious diseases, the company's TB vaccine development program represents a critical effort in the global fight against TB. By pursuing advanced vaccine solutions, Cha Vaccine Research Institute is at the forefront of efforts to reduce TB incidence and mortality.

• Cancer Vaccine

  Expanding its research horizons, the institute is also venturing into the development of vaccines against cancer. This initiative underscores the company's dedication to leveraging vaccine technology in the battle against chronic diseases, aiming to offer new hope through innovative therapeutic vaccines.